Cited by 242Endometriosis Research and TreatmentOvarian cancer diagnosis and treatmentEndometrial and Cervical Cancer Treatments

Ovarian and extraovarian endometriosis-associated cancer

Modesitt, S·2002·Obstetrics & Gynecology

Abstract

OBJECTIVE: To determine clinical characteristics of women with endometriosis-associated intraperitoneal cancers, to assess differences based on the relationship of the cancer to the endometriosis, and to assess factors associated with survival. METHODS: A search of medical records at The University of Texas M. D. Anderson Cancer Center from 1970 to 1999 identified patients who had synchronous endometriosis and intraperitoneal cancer. Demographic and clinicopathologic characteristics were evaluated for differences based on the relationship of the cancer to the endometriosis and for correlation with survival. RESULTS: One hundred fifteen patients were identified: 25 patients with ovarian cancer arising in endometriosis, 21 with an extraovarian cancer arising in endometriosis, 33 patients with endometriosis and ovarian cancer in the same location but without a definite transition point, and 36 patients with ovarian cancer and incidental endometriosis. Women with extraovarian cancers arising in endometriosis were more likely to be postmenopausal (P <.001) and use hormone replacement (P <.001). The median age was 47 years, the most common histological tumor types were clear cell and endometrioid (23% each), and the most common stage was stage I (31%). The median survival was 35 months. Univariate survival analysis revealed that gravidity (P <.038), grade (P <.001), stage (P <.001), histology (P <.01), and type of chemotherapy (P <.011) correlated with survival. Multivariable analysis revealed that stage and gravidity independently predicted survival. CONCLUSION: Women with endometriosis-associated cancers are typically premenopausal, have a high incidence of endometrioid and clear cell histologies, and have early stage disease. Stage and gravidity independently predicted survival.

Integrity signals

Registry

Crossref · 10.1016/s0029-7844(02)02149-x

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Modesitt et al. (2002) observed transition points in endometriosis-associated tumors, where benign endometriotic glands blend with atypical and overtly malignant glands.

    “The study by Modesitt et al. (2002) noted the presence of ‘‘transition points’’ in such tumors, where a benign endometriotic gland was observed blending with atypical and overtly malignant glands [16].”

The citation lists haven’t been fetched yet

References 26 · Cited by 242

Authors
Modesitt, S.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Venue
Obstetrics & Gynecology
Published
2002-10
Volume
100
Issue
4
Pages
788-795
ISSN
0029-7844 (ISSN-L)
OpenAlex
W2044887932
Cited by
242
References
26
Citations by year
2026: 2 · 2025: 1 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 12 · 2020: 14 · 2019: 13 · 2018: 13 · 2017: 5 · 2016: 9 · 2015: 17 · 2014: 10 · 2013: 11 · 2012: 19
FWCI
8.80
Type
journal article
Language
en
Open access
closed
Locations
  • Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords
endometriosis-associated cancer, ovarian cancer, synchronous tumors, tumor stage, gravidity, endometrioid carcinoma, clear cell carcinoma, hormone replacement therapy, postmenopausal women
MeSH terms
Combined Modality Therapy, Endometriosis, Female, Humans, Middle Aged, Ovarian Neoplasms, Peritoneal Neoplasms, Retrospective Studies, Risk Factors, Proportional Hazards Models, Survival Analysis, Case-Control Studies, Adenocarcinoma, Clear Cell, Carcinoma, Endometrioid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review